Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide

Wang,Nan; Zhu,Peining; Huang,Renxuan; Sun,Liankun; Dong,Delu; Gao,Yufei

doi:10.3892/etm.2021.10681

Suppressing TRAP1 sensitizes glioblastoma multiforme cells to temozolomide

Authors:
- Nan Wang
- Peining Zhu
- Renxuan Huang
- Liankun Sun
- Delu Dong
- Yufei Gao
View Affiliations

Affiliations: Department of Neurosurgery, China‑Japan Union Hospital, Jilin University, Changchun, Jilin 130000, P.R. China, Key Laboratory of Pathobiology, Ministry of Education, Department of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130000, P.R. China
Published online on: September 2, 2021 https://doi.org/10.3892/etm.2021.10681
Article Number: 1246
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioma is a common malignant tumor of the central nervous system, accounting for ~50% of intracranial tumors. The current standard therapy for glioma is surgical resection followed by postoperative adjuvant radiotherapy and temozolomide (TMZ) chemotherapy. However, resistance to TMZ is one of the factors affecting prognosis. It has been reported that TNF receptor‑associated protein 1 (TRAP1) is overexpressed in numerous types of tumor and that interfering with its function may abrogate chemotherapy resistance. TRAP1 inhibitor Gamitrinib triphenylphosphonium (G‑TPP) and shRNA were used in the present study to suppress the function of this molecule in glioblastoma multiforme (GBM) cell lines. MTT assay was performed to evaluate the combined effect of G‑TPP and TMZ treatment. To investigate the underlying mechanism responsible for this combined effect, the mitochondrial unfolded protein response (mtUPR), mitophagy, mitochondrial fusion and reactive oxygen species (ROS) were quantified using western blotting and immunofluorescence techniques. TMZ treatment induced apoptosis in GBM cells by activating the p53 pathway, whilst simultaneously downregulating mitophagy and enhancing mitochondrial fusion. The latter may occur in order to compensate for the defect caused by downregulated mitophagy. Suppressing the function of TRAP1 disturbed this compensatory mechanism by inducing mtUPR, which resulted in a burst of ROS formation and sensitized the GBM cells to the effects of TMZ treatment. Thus, suppressing the function of TRAP1 sensitized GBM cells to TMZ lysis by inducing mtUPR and the subsequent ROS burst. TRAP1 is therefore considered to be a promising target for GBM therapy.

View Figures

View References

1	Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 16 (Suppl 4):iv1–iv63. 2014.PubMed/NCBI View Article : Google Scholar
2	Wirsching HG, Galanis E and Weller M: Glioblastoma. Handb Clin Neurol. 134:381–397. 2016.PubMed/NCBI View Article : Google Scholar
3	Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996. 2005.PubMed/NCBI View Article : Google Scholar
4	Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 370:699–708. 2014.PubMed/NCBI View Article : Google Scholar
5	Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, et al: Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. J Clin Oncol. 31:4085–4091. 2013.PubMed/NCBI View Article : Google Scholar
6	Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009.PubMed/NCBI View Article : Google Scholar
7	Liu P, Li P, Lei T, Qu L, Huang H and Mu Q: Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature. Oncol Lett. 15:8663–8668. 2018.PubMed/NCBI View Article : Google Scholar
8	Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin MD, Karpel-Massler G, Debatin KM and Westhoff MA: Temozolomide and other alkylating agents in glioblastoma therapy. Biomedicines. 7(69)2019.PubMed/NCBI View Article : Google Scholar
9	Oike T, Suzuki Y, Sugawara K, Shirai K, Noda SE, Tamaki T, Nagaishi M, Yokoo H, Nakazato Y and Nakano T: Radiotherapy plus concomitant adjuvant temozolomide for glioblastoma: Japanese mono-institutional results. PLoS One. 8(e78943)2013.PubMed/NCBI View Article : Google Scholar
10	Lee SY: Temozolomide resistance in glioblastoma multiforme. Genes Dis. 3:198–210. 2016.PubMed/NCBI View Article : Google Scholar
11	Hoter A and El-Sabban ME: The HSP90 family: Structure, regulation, function, and implications in health and disease. Int J Mol Sci. 19(2560)2018.PubMed/NCBI View Article : Google Scholar
12	Altieri DC: Hsp90 regulation of mitochondrial protein folding: From organelle integrity to cellular homeostasis. Cell Mol Life Sci. 70:2463–2472. 2013.PubMed/NCBI View Article : Google Scholar
13	Altieri DC, Stein GS and Lian JB: TRAP-1, the mitochondrial Hsp90. Biochim Biophys Acta. 1823:767–773. 2012.PubMed/NCBI View Article : Google Scholar
14	Dutta R and Inouye M: GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci. 25:24–28. 2000.PubMed/NCBI View Article : Google Scholar
15	Meyer P, Prodromou C, Hu B, Vaughan C, Roe SM, Panaretou B, Piper PW and Pearl LH: Structural and functional analysis of the middle segment of hsp90: Implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell. 11:647–658. 2003.PubMed/NCBI View Article : Google Scholar
16	Soti C, Vermes Á, Haystead TA and Csermely P: Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide afﬁnity cleavage: A distinct nucleotide speciﬁcity of the C-terminal ATP-binding site. Eur J Biochem. 270:2421–2428. 2003.PubMed/NCBI View Article : Google Scholar
17	Siegelin MD, Dohi T, Raskett CM, Orlowski GM, Powers CM, Gilbert CA, Ross AH, Plescia J and Altieri DC: Exploiting the mitochondrial unfolded protein response for cancer therapy in mice and human cells. J Clin Invest. 121:1349–1360. 2011.PubMed/NCBI View Article : Google Scholar
18	Kang BH and Altieri DC: Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones. Oncogene. 28:3681–3688. 2009.PubMed/NCBI View Article : Google Scholar
19	Masgras I, Sanchez-Martin C and Colombo G: The chaperone TRAP1 as a modulator of the mitochondrial adaptations in cancer cells. Front Oncol. 7(58)2017.PubMed/NCBI View Article : Google Scholar
20	Zhang D, Dai D, Zhou M, Li Z, Wang C, Lu Y, Li Y and Wang J: Inhibition of Cyclin D1 expression in human glioblastoma cells is associated with increased temozolomide chemosensitivity. Cell Physiol Biochem. 51:2496–2508. 2018.PubMed/NCBI View Article : Google Scholar
21	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010.PubMed/NCBI View Article : Google Scholar
22	Im CN: Past, present, and emerging roles of mitochondrial heat shock protein TRAP1 in the metabolism and regulation of cancer stem cells. Cell Stress Chaperones. 21:553–562. 2016.PubMed/NCBI View Article : Google Scholar
23	Marchenko ND: Mitochondrial death functions of p53. Mol Cell Oncol. 1(e955995)2014.PubMed/NCBI View Article : Google Scholar
24	Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M and Green DR: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science. 303:1010–1014. 2004.PubMed/NCBI View Article : Google Scholar
25	Kulek AR, Anzell A, Wider JM, Sanderson TH and Przyklenk K: Mitochondrial quality control: Role in cardiac models of lethal ischemia-reperfusion injury. Cells. 9(214)2020.PubMed/NCBI View Article : Google Scholar
26	Baqri RM, Pietron AV, Gokhale RH, Turner BA, Kaguni LS, Shingleton AW, Kunes S and Miller KE: Mitochondrial chaperone TRAP1 activates the mitochondrial UPR and extends healthspan in Drosophila. Mech Ageing Dev. 141-142:35–45. 2014.PubMed/NCBI View Article : Google Scholar
27	Takemoto K, Miyata S, Takamura H, Katayama T and Tohyama M: Mitochondrial TRAP1 regulates the unfolded protein response in the endoplasmic reticulum. Neurochem Int. 58:880–887. 2011.PubMed/NCBI View Article : Google Scholar
28	Zhang L, Wang X, Cueto R, Effi C, Zhang Y, Tan H, Qin X, Ji Y, Yang X and Wang H: Biochemical basis and metabolic interplay of redox regulation. Redox Biol. 26(101284)2019.PubMed/NCBI View Article : Google Scholar
29	Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, Castoria G and Migliaccio A: ROS in cancer therapy: The bright side of the moon. Exp Mol Med. 52:192–203. 2020.PubMed/NCBI View Article : Google Scholar
30	Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, Mampre D, Jackson C, Peterson J, Trifiletti D, Hammack J, Ortiz K, Lesser E, et al: Trends in glioblastoma: Outcomes over time and type of intervention: A systematic evidence based analysis. J Neurooncol. 147:297–307. 2020.PubMed/NCBI View Article : Google Scholar
31	Weller M, Le Rhun E, Preusser M, Tonn JC and Roth P: How we treat glioblastoma. ESMO Open. 4 (Suppl 2)(e000520)2019.PubMed/NCBI View Article : Google Scholar
32	Pietrafesa M, Maddalena F, Possidente L, Condelli V, Zoppoli P, Li Bergolis V, Rodriquenz MG, Aieta M, Vita G, Esposito F and Landriscina M: Gene copy number and Post-transductional mechanisms regulate TRAP1 expression in human colorectal carcinomas. Int J Mol Sci. 21(145)2019.PubMed/NCBI View Article : Google Scholar
33	Lettini G, Maddalena F, Sisinni L, Condelli V, Matassa DS, Costi MP, Simoni D, Esposito F and Landriscina M: TRAP1: A viable therapeutic target for future cancer treatments? Expert Opin Ther Targets. 21:805–815. 2017.PubMed/NCBI View Article : Google Scholar
34	Hua G and Zhang Q: Heat shock protein 75 (TRAP1) antagonizes reactive oxygen species generation and protects cells from granzyme M-mediated apoptosis. J Biol Chem. 282:20553–20560. 2007.PubMed/NCBI View Article : Google Scholar
35	Zhang P, Lu Y, Yu D, Zhang D and Hu W: TRAP1 provides protection against myocardial ischemia-reperfusion injury by ameliorating mitochondrial dysfunction. Cell Physiol Biochem. 36:2072–2082. 2015.PubMed/NCBI View Article : Google Scholar
36	Kazlauskaite A, Kondapalli C, Gourlay R, Campbell DG, Ritorto MS, Hofmann K, Alessi DR, Knebel A, Trost M and Muqit MM: Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem J. 460:127–139. 2014.PubMed/NCBI View Article : Google Scholar
37	Goiran T, Duplan E, Rouland L, El Manaa W, Lauritzen I, Dunys J, You H, Checler F and Alves da Costa C: Nuclear p53-mediated repression of autophagy involves PINK1 transcriptional down-regulation. Cell Death Differ. 25:873–884. 2018.PubMed/NCBI View Article : Google Scholar
38	Lin Q, Li S, Jiang N, Shao X, Zhang M, Jin H, Zhang Z, Shen J, Zhou Y, Zhou W, et al: PINK1-parkin pathway of mitophagy protects against contrast-induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation. Redox Biol. 26(101254)2019.PubMed/NCBI View Article : Google Scholar
39	Singh A, Kukreti R, Saso L and Kukreti S: Oxidative stress: A key modulator in neurodegenerative diseases. Molecules. 24(1583)2019.PubMed/NCBI View Article : Google Scholar
40	Ozben T: Oxidative stress and apoptosis: Impact on cancer therapy. J Pharm Sci. 96:2181–2196. 2007.PubMed/NCBI View Article : Google Scholar
41	Simon HU, Haj-Yehia A and Levi-Schaffer F: Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis. 5:415–418. 2000.PubMed/NCBI View Article : Google Scholar
42	Poetsch AR: The genomics of oxidative DNA damage, repair, and resulting mutagenesis. Comput Struct Biotechnol J. 18:207–219. 2020.PubMed/NCBI View Article : Google Scholar
43	Shan F, Shao Z and Jiang S: Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways. Cancer Med. 5:3166–3175. 2016.PubMed/NCBI View Article : Google Scholar